Quantitative FDG-PET: a new biomarker in PMBCL
- PMID: 26294712
- DOI: 10.1182/blood-2015-07-653386
Quantitative FDG-PET: a new biomarker in PMBCL
Abstract
In this issue of Blood, Ceriani et al introduce, in primary mediastinal B-cell lymphoma (PMBCL), a new prognostic factor measured on pretreatment 18F-fluorodeoxyglucose (18FDG)-positron emission tomography (PET)/computed tomography (CT): the total lesion glycolysis (TLG), which is an index of the glucose uptake by the total tumor burden. This paper is part of the International Extranodal Lymphoma Study Group (IELSG) 26 prospective study designed to evaluate the role of PET in the treatment of PMBCL.
Comment on
-
Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma.Blood. 2015 Aug 20;126(8):950-6. doi: 10.1182/blood-2014-12-616474. Epub 2015 Jun 18. Blood. 2015. PMID: 26089397 Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources

